Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (June 2019)
33 slides from Astrazeneca's investor day presentation, Jun 3, 2019
Slide 1: Meet AZN management: ASCO 2019 Opening session
Marquis_CONFERENCE AZ2019 Meet AZN management: ASCO 2019 Opening session Pascal Soriot, Chief Executive Officer José Baselga, Executive Vice President, Oncology R&D 3 June 2019
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Presenters
Presenters Pascal Soriot Dave Fredrickson Klaus Edvardsen for breakout sessions Additional presenters Executive Director and Executive Vice President, Senior Vice President, Chief Executive Officer Oncology Business Unit Oncology R&D, late stage Greg Rossi Susan Galbraith Vice President, Lynparza Se
Slide 4: Agenda
Agenda Strategy and business ASCO 2019 highlights - Lynparza pancreatic cancer (POLO trial) - Lynparza 3rd-line ovarian cancer (SOLO3 trial) - Other highlights Breakout sessions followed by drinks and canapés 4
Slide 5: Cancer is still a growing burden
Cancer is still a growing burden 2018 2030 estimate 18.1 million 26.4 million new patients new patients 9.6 million 17 million deaths deaths 43 million 82 million patients living patients living with cancer with cancer Source: International Agency for Research on Cancer. 5
Slide 6: Oncology: strategy
Oncology: strategy A leading, diversified oncology business Lung cancer Multiple cancers Multiple cancers Haematology trastuzumab deruxtecan • Stage IV NSCLC1 • Unresectable, • Ovarian, breast • DS4 collaboration • First medicine in T790Mm2 / Stage III NSCLC cancers • Next: HER2+5 haematology EGFRm3
Slide 7: Lung cancer: Tagrisso
Lung cancer: Tagrisso Realising global opportunity in patients with 1st-line EGFRm disease Strong performance in all 1st-line opportunity Lifecycle plans include early $m markets: +92% in Q1 2019 is moving global stage and combinations 700 Phase III FLAURA trial almost doubled progression-free survi
Slide 8: Lung cancer: Imfinzi
Lung cancer: Imfinzi Global adoption underway; lifecycle trials will expand to more patients Ex-US now 22% of total, Major ongoing Phase III trials $m up from 18% in Q4 2018 with Imfinzi used as backbone 300 AEGEAN ADJUVANT (2020) (2020+) 250 NIAGARA PACIFIC-5 ADRIATIC EMERALD (2020+) (2020+) (2020+
Slide 9: Lynparza
Lynparza Strong performance; industry-leading development programme Seven quarters of strong Extensive, strategic development programme underway $m growth: +105% in Q1 2019 Novel Ex-US now 50% of total adjuvant combinations Earlier lines breast of treatment OlympiA Merck combinations 250 1st-line ov
Slide 10: Trastuzumab deruxtecan and Calquence
Trastuzumab deruxtecan and Calquence Important future platforms with significant growth Trastuzumab deruxtecan: unprecedented efficacy in Haematology taking shape: Calquence heavily-pretreated HER2+ metastatic breast cancer on track to benefit patients globally 59.5% CLL confirmed objective response
Slide 11: Agenda
Agenda Strategy and business ASCO 2019 highlights - Lynparza pancreatic cancer (POLO trial) - Lynparza 3rd-line ovarian cancer (SOLO3 trial) - Other highlights Breakout sessions followed by drinks and canapés 11
Slide 12: ASCO 2019 highlights
ASCO 2019 highlights Solid AstraZeneca Data highlights from select presence at ASCO 2019 mid-to-late stage trials • 93 abstracts accepted, including 12 orals and 11 • Lynparza poster discussions Phase III POLO - BRCAm pancreatic cancer Phase III SOLO3 - BRCAm ovarian cancer • Externally-sponsored ~4
Slide 13: Agenda
Agenda Strategy and business ASCO 2019 highlights - Lynparza pancreatic cancer (POLO trial) - Lynparza 3rd-line ovarian cancer (SOLO3 trial) - Other highlights Breakout sessions followed by drinks and canapés 13
Slide 14: Lynparza Pancreatic cancer - POLO trial
Lynparza Pancreatic cancer - POLO trial 14
Slide 15: Lynparza Pancreatic cancer - POLO trial
Lynparza Pancreatic cancer - POLO trial 15
Slide 16: Lynparza Pancreatic cancer - POLO trial
Lynparza Pancreatic cancer - POLO trial 16
Slide 17: Lynparza Pancreatic cancer - POLO trial
Lynparza Pancreatic cancer - POLO trial 17
Slide 18: Lynparza Pancreatic cancer - POLO trial
Lynparza Pancreatic cancer - POLO trial 18
Slide 19: Lynparza Pancreatic cancer - POLO trial
Lynparza Pancreatic cancer - POLO trial 19
Slide 20: Lynparza Pancreatic cancer - POLO trial
Simultaneous Lynparza publication in The New England Journal of Pancreatic cancer - POLO trial Medicine 20
Slide 21: Agenda
Agenda Strategy and business ASCO 2019 highlights - Lynparza pancreatic cancer (POLO trial) - Lynparza 3rd-line ovarian cancer (SOLO3 trial) - Other highlights Breakout sessions followed by drinks and canapés 21
Slide 22: Lynparza Ovarian cancer - SOLO3 trial
Lynparza Ovarian cancer - SOLO3 trial 22
Slide 23: Lynparza Ovarian cancer - SOLO3 trial
Lynparza Ovarian cancer - SOLO3 trial 23
Slide 24: Lynparza Ovarian cancer - SOLO3 trial
Lynparza Ovarian cancer - SOLO3 trial 24
Slide 25: Lynparza Ovarian cancer - SOLO3 trial
Lynparza Ovarian cancer - SOLO3 trial 25
Slide 26: Lynparza Ovarian cancer - SOLO3 trial
Lynparza Ovarian cancer - SOLO3 trial 26
Slide 27: Lynparza Ovarian cancer - SOLO3 trial
Lynparza Ovarian cancer - SOLO3 trial 27
Slide 28: Agenda
Agenda Strategy and business ASCO 2019 highlights - Lynparza pancreatic cancer (POLO trial) - Lynparza 3rd-line ovarian cancer (SOLO3 trial) - Other highlights Breakout sessions followed by drinks and canapés 28
Slide 29: Other highlights: AstraZeneca continues to redefine cancer treatment
Other highlights AstraZeneca continues to redefine cancer treatment Breaking Treating patients Raising the bar for Advancing treatment earlier in their better outcomes presence in boundaries disease haematology Lynparza Imfinzi Tagrisso Calquence prostate cancer NSCLC NSCLC CLL Phase II TOPARP-B Pha
Slide 30: Agenda
Agenda Strategy and business ASCO 2019 highlights - Lynparza pancreatic cancer (POLO trial) - Lynparza 3rd-line ovarian cancer (SOLO3 trial) - Other highlights Breakout sessions followed by drinks and canapés 30
Slide 31: Breakout sessions
Breakout sessions Breakout sessions Room E F Four topics Same as opening session -sales and marketing 18:30 -late-stage pipeline -early-stage pipeline Sales and Topic Early-stage pipeline -trastuzumab deruxtecan marketing Susan Galbraith Dave Fredrickson Hosts Jean-Charles Soria Greg Rossi One time
Slide 32: Investor Relations
Investor Relations Thomas Kudsk Larsen Nick Stone Jen Kretzmann thomas.larsen@astrazeneca.com nick.stone@astrazeneca.com jennifer.kretzmann@astrazeneca.com T: +44 20 3749 5712 T: +44 20 3749 5716 T: +44 20 3749 5824 M: +44 7818 524185 M: +44 7717 618834 M: +44 7469 408333 Henry Wheeler Josie Afolabi
Slide 33: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non- commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availab